Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
REDWOOD CITY, Calif., May 03, 2017 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2017 financial results on Monday, May 8th, 2017. OncoMed management will host a conference call and webcast to review 2017 first-quarter financial results and provide a corporate update at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-855-420-0692 (domestic) and 1-484-756-4194 (international) using the conference ID# 18252865. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com, and will be available for replay through August 31, 2017.
An audio replay of the conference call can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer/ immuno-oncology therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. Demcizumab (anti-DLL4, OMP-21M18), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company’s strategic alliances with Celgene Corporation. OncoMed is independently developing vantictumab (anti-Fzd, OMP-18R5), ipafricept (Fzd8-Fc, OMP-54F28) and GITRL-Fc (OMP-336B11), as well as continuing to pursue new immuno-oncology drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact Peter Rahmer Trout Group [email protected] (646) 378-2973 Mike Zanoni Trout Group [email protected] (646) 378-2924
